Skip to content

US · PBH · MEDICAL - DISTRIBUTION

Prestige Consumer Healthcare Inc. (PBH) intrinsic value and stock valuation

$49.63as of 2026-11-21 · Mkt cap 2.51B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Prestige Consumer Healthcare Inc. DCF and intrinsic value

InvestorsCraft values PBH with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from PBH’s statements →

Prestige Consumer Healthcare Inc. Graham Number

Graham Number: $58.67d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Distribution Tarrytown, NY 10591 prestigebrands.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$1.09B+2.9% 5y CAGRd
20122026
Net income
$190.3M+2.9% 5y CAGRd
20122026
Free cash flow
$254.2M+3.6% 5y CAGRd
20122026
Total equity
$1.89B+6.8% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$1.09B$1.14B$1.13B$1.13B$1.09B
Operating income$309.4M$336.8M$342.4M-$-22.41M$329.9M
Net income$190.3M$214.6M$209.3M-$-82.31M$205.4M
EPSd$3.91M$4.29M$4.17M-$-1.65M$4.04M
Operating cash flow$265.4M$251.5M$248.9M$229.7M$259.9M
Capital expenditure-$-11.18M-$-8.22M-$-9.55M-$-7.78M-$-9.64M
Free cash flow$254.2M$243.3M$239.4M$221.9M$250.3M
Total assets$3.55B$3.4B$3.32B$3.35B$3.67B
Total debt$1.05B$1.04B$1.14B$1.37B$1.51B
Net debt$981.6M$946.4M$1.09B$1.31B$1.48B
Total equity$1.89B$1.83B$1.66B$1.45B$1.58B
Cash and short-term investments$63.9M$97.9M$46.5M$58.5M$27.2M
Income statement
20262025202420232022
Revenue$1.09B$1.14B$1.13B$1.13B$1.09B
Cost of revenue$514.1M$503.3M$500.9M$502.4M$466.2M
Gross profit$574.6M$634.5M$624.5M$625.3M$620.7M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$265.2M$263.9M$259.5M$252.4M$264.8M
Other expenses$0.00$33.8M$22.6M$395.3M$25.9M
Operating expenses$265.2M$297.7M$282M$647.7M$290.7M
Cost and expenses$779.3M$801M$782.9M$1.15B$756.9M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$42.3M$47.6M$67.2M$69.2M$64.3M
Depreciation and amortization$31.3M$30.2M$30.7M$32.6M$32.1M
Ebitda$331.1M$362M$373.9M$7.87M$358.8M
Operating income$309.4M$336.8M$342.4M-$-22.41M$329.9M
Total other income/expenses, net-$-51.91M-$-52.59M-$-66.4M-$-71.5M-$-67.46M
Income before tax$257.5M$284.2M$276M-$-93.92M$262.5M
Income tax expense$67.2M$69.6M$66.7M-$-11.61M$57.1M
Net income$190.3M$214.6M$209.3M-$-82.31M$205.4M
Weighted average shares outstanding$48.5M$49.7M$49.8M$49.9M$50.3M
Weighted average diluted shares outstanding$48.7M$50.1M$50.2M$49.9M$50.8M
Balance sheet
20262025202420232022
Cash and short-term investments$63.9M$97.9M$46.5M$58.5M$27.2M
Net receivables$191.9M$194.3M$176.8M$167M$139.3M
Inventory$159.1M$147.7M$138.7M$162.1M$120.3M
Total current assets$431.5M$448.3M$375M$391.7M$293.3M
Property, plant and equipment, net$171.3M$127.8M$89.3M$89.5M$98.5M
Goodwill and intangible assets$2.88B$2.82B$2.85B$2.87B$3.28B
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.12B$2.95B$2.94B$2.96B$3.38B
Total assets$3.55B$3.4B$3.32B$3.35B$3.67B
Accounts payable$22.8M$18.9M$39M$62.7M$55.8M
Short-term debt$12.6M$8.54M$6.15M$9.76M$9.11M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$120.9M$106.6M$117.1M$160.7M$143.4M
Long-term debt$1.03B$1.04B$1.13B$1.36B$1.5B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.54B$1.46B$1.55B$1.75B$1.95B
Capital lease obligations$48.5M$51.9M$13.9M$21.3M$29.7M
Total liabilities$1.66B$1.57B$1.66B$1.91B$2.09B
Common stock$560K$560K$560K$550K$540K
Retained earnings$1.75B$1.56B$1.34B$1.13B$1.21B
Accumulated other comprehensive income (loss)-$-28.37M-$-37.66M-$-34.49M-$-31.56M-$-19.03M
Total equity$1.89B$1.83B$1.66B$1.45B$1.58B
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.05B$1.04B$1.14B$1.37B$1.51B
Net debt$981.6M$946.4M$1.09B$1.31B$1.48B
Cash flow statement
20262025202420232022
Net income$190.3M$214.6M$209.3M-$-82.31M$205.4M
Depreciation and amortization$31.3M$30.2M$30.7M$32.6M$32.1M
Stock-based compensation$0.00$11.2M$14M$12.4M$9.04M
Change in working capital-$-9.84M-$-41.94M-$-39.83M-$-53.85M-$-10.95M
Accounts receivable-$-3.69M-$-16.33M-$-6.32M-$-24.93M-$-24.65M
Inventory-$-1.6M-$-9.31M$24.4M-$-42.23M$660K
Accounts payable-$-150K-$-19.41M-$-24.97M$7.26M$9.15M
Net cash provided by operating activities$265.4M$251.5M$248.9M$229.7M$259.9M
Investments in property, plant and equipment-$-11.18M-$-8.22M-$-9.55M-$-7.78M-$-9.64M
Acquisitions, net-$-123.74M-$-9.23M-$-10.56M-$-3.8M-$-246.87M
Net cash used for investing activities-$-136.84M-$-17.45M-$-20.11M-$-11.58M-$-256.51M
Common stock issued$4.29M$14.8M$0.00$0.00$0.00
Common stock repurchased-$-156.28M-$-51.51M-$-25M-$-50M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-163.84M-$-182.07M-$-241.01M-$-185.85M-$-7.57M
Net change in cash-$-34.02M$51.4M-$-12.02M$31.3M-$-5.12M
Cash at end of period$63.9M$97.9M$46.5M$58.5M$27.2M
Operating cash flow$265.4M$251.5M$248.9M$229.7M$259.9M
Capital expenditure-$-11.18M-$-8.22M-$-9.55M-$-7.78M-$-9.64M
Free cash flow$254.2M$243.3M$239.4M$221.9M$250.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Prestige Consumer Healthcare Inc.

        Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.

        CEO
        Ronald Lombardi
        Employees
        890
        Beta
        0.35

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Prestige Consumer Healthcare Inc. (PBH)?

        Prestige Consumer Healthcare Inc. (PBH) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PBH undervalued?

        PBH trades at a price of $49.63 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.